Unveiling the Role of Epigenetic Shifts in Pancreatic Cancer's Spread
A groundbreaking study from Johns Hopkins Medicine has shed light on a novel mechanism driving the spread of pancreatic cancer. Researchers have discovered that a gene named KLF5 plays a pivotal role in fueling the growth of metastatic tumors, not by altering the DNA code itself, but by modifying chemical changes and DNA organization, known as epigenetics. This finding opens up new avenues for potential treatments, as it challenges the traditional understanding of cancer progression.
The study, led by Dr. Andrew Feinberg, reveals that epigenetic alterations are often overlooked as a significant contributor to cancer metastasis. In 2017, Dr. Feinberg and his team found that individuals with the most common form of pancreatic cancer exhibited widespread epigenetic changes in their primary tumors, rather than new mutations in the DNA code. This discovery prompted further investigation into the impact of epigenetic shifts on cancer cell behavior.
To identify the most influential genes in cancer cell growth, the scientists employed a gene-editing technology called CRISPR. By silencing specific genes and observing the resulting impact on cell growth, they found that KLF5 had the most significant effect on promoting the growth and invasion of metastatic cells. Interestingly, increased KLF5 gene expression was detected in the metastatic lesions of 10 out of 13 pancreatic cancer patients, compared to their primary tumors.
The research team also conducted additional experiments to validate KLF5's role. They discovered that KLF5 controls the tight packaging of DNA, an epigenetic factor that regulates gene expression. This finding suggests that even slight changes in KLF5 expression levels can significantly impact the cells' ability to grow and spread, offering a potential avenue for targeted treatment.
Furthermore, the study revealed that KLF5 regulates two other genes, NCAPD2 and MTHFD1, which are known as epigenetic modifier genes. These genes influence gene expression by adding chemical groups to DNA, altering its packaging. This discovery reinforces the idea that cancer metastasis is often driven by epigenetic changes rather than additional mutations.
The implications of this research are far-reaching. By understanding the role of KLF5 and its epigenetic modifications, scientists may develop more effective treatments for pancreatic cancer metastasis. The study's findings also emphasize the importance of considering epigenetic factors in cancer research, potentially leading to new therapeutic approaches.
The research was supported by various grants from the National Institutes of Health and a Celgene License Pathway Agreement. The study's authors include Dr. Andrew Feinberg and several other scientists from Johns Hopkins Medicine, Yale University, and NYU Langone Health.
This groundbreaking research highlights the complexity of cancer biology and the potential for epigenetic shifts to drive cancer progression. As the study's authors conclude, further exploration of KLF5 and its epigenetic modifications may lead to innovative treatments for pancreatic cancer and beyond.
